Literature DB >> 10749145

Both normal and transforming PCPH proteins have guanosine diphosphatase activity but only the oncoprotein cooperates with Ras in activating extracellular signal-regulated kinase ERK1.

J A Recio1, J G Páez, B Maskeri, M Loveland, J A Velasco, V Notario.   

Abstract

Previous reports from our laboratory described the activation of the PCPH gene into the PCPH oncogene (mt-PCPH, reported previously as Cph) by a single point mutational deletion. As a consequence, the mt-PCPH oncoprotein is a truncated form of the normal PCPH protein. Although both proteins have ribonucleotide diphosphate-binding activity, only mt-PCPH acted synergistically with a human H-Ras oncoprotein to transform murine NIH3T3 fibroblasts. We report here the expression of the PCPH and mt-PCPH proteins in Escherichia coli and the finding that the purified bacterial recombinant proteins have intrinsic guanosine diphosphatase (GDPase) activity. However, expression of the Syrian hamster PCPH and mt-PCPH proteins in haploid yeast strains engineered to be GDPase deficient by targeted disruption of the single GDA1 allele did not complement their glycosylation-disabled phenotype, suggesting the existence of significant functional differences between the mammalian and yeast enzymes. Results from transient cotransfections into NIH3T3, COS-7, or 293T cells indicated that, in mammalian cells, both PCPH and mt-PCPH cause an overall down-regulation of the stimulatory effect of epidermal growth factor or the activated ras or raf oncogenes on the Ras/mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling pathway. However, despite this overall negative regulatory role on Ras signaling, mt-PCPH, but not PCPH, cooperated with the Ras oncoprotein to produce a prolonged stimulation of the phosphorylation of ERK1 but had no effect on the phosphorylation levels of ERK2. These results represent a clear difference between the mechanisms of action of PCPH and mt-PCPH and suggest that the ability to cause a sustained activation of ERK1 may be an important determinant of the transforming activity of mt-PCPH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749145

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Ras mutation impairs epithelial barrier function to a wide range of nonelectrolytes.

Authors:  James M Mullin; James M Leatherman; Mary Carmen Valenzano; Erika Rendon Huerta; Jon Verrechio; David M Smith; Karen Snetselaar; Mantao Liu; Mary Kay Francis; Christian Sell
Journal:  Mol Biol Cell       Date:  2005-09-21       Impact factor: 4.138

2.  The GDA1_CD39 superfamily: NTPDases with diverse functions.

Authors:  Aileen F Knowles
Journal:  Purinergic Signal       Date:  2011-01-21       Impact factor: 3.765

3.  PCPH/ENTPD5 expression confers to prostate cancer cells resistance against cisplatin-induced apoptosis through protein kinase Calpha-mediated Bcl-2 stabilization.

Authors:  Joaquín Villar; Humair S Quadri; Insun Song; York Tomita; Oscar M Tirado; Vicente Notario
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 4.  NTPDase5/PCPH as a new target in highly aggressive tumors: a systematic review.

Authors:  Paula Andreghetto Bracco; Ana Paula Santin Bertoni; Márcia Rosângela Wink
Journal:  Biomed Res Int       Date:  2014-06-23       Impact factor: 3.411

5.  ENTPD5: identification of splicing variants and their impact on cancer survival.

Authors:  Rafael Paschoal de Campos; Marcia Rosângela Wink; Guido Lenz
Journal:  Purinergic Signal       Date:  2021-06-02       Impact factor: 3.765

6.  The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family.

Authors:  Caitlin M MacCarthy; Vicente Notario
Journal:  Int J Oncol       Date:  2013-08-06       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.